---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-020841"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:44:32.838344+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vera Therapeutics reports Q1 net loss of $30.1M; atacicept Phase 3 to start Q2 2023

## Summary
- Net loss of $30.1M ($0.80 per diluted share) vs $17.1M ($0.71) in Q1 2022.
- Cash, cash equivalents, and marketable securities of $197.2M as of March 31, 2023; expected to fund operations to early 2026.
- 36-week data from Phase 2b ORIGIN trial of atacicept in IgAN selected as late-breaking presentation at ERA Congress 2023.
- Plan to initiate pivotal Phase 3 trial of atacicept in IgAN in Q2 2023.
- Appointed Kerry Cooper, M.D., as Senior Vice President of Medical Affairs.

## SEC filing metadata
- accession: 0000950170-23-020841
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000095017023020841/0000950170-23-020841-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000095017023020841/vera-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-020841
- JSON: https://secwatch.observer/filing/0000950170-23-020841.json
- Plain text: https://secwatch.observer/filing/0000950170-23-020841.txt

## Key facts
- Earnings Releases
  Vera Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: net income net loss of $30.1 million, EPS net loss per diluted share of $0.80.
  - Period: the first quarter ended March 31, 2023
  - Net income: net loss of $30.1 million
  - EPS: net loss per diluted share of $0.80
  - Result: reported results
  source text: For the quarter ended March 31, 2023, the company reported a net loss of $30.1 million, or a net loss per diluted share of $0.80
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831828/000095017023020841/0000950170-23-020841-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.